Exelixis earnings were $643.6M for the trailing 12 months ending Mar 31, 2025, with 251.6% growth year over year. The latest EXEL earnings report on Mar 31, 2025 announced Q1 2025 earnings of $159.6M, up 14.1% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, EXEL reported annual earnings of $521.3M, with 150.9% growth. The next EXEL earnings date is Aug 12, 2025.
EXEL past earnings growth
How has EXEL's earnings growth performed historically?
On EXEL's earnings call on Invalid Date, Exelixis (NASDAQ: EXEL) reported Q1 2025 earnings per share (EPS) of $0.57, up 375% year over year. Total EXEL earnings for the quarter were $159.62 million. In the same quarter last year, Exelixis's earnings per share (EPS) was $0.12.
The next EXEL earnings call is Invalid Date. Add EXEL to your watchlist to be reminded of Exelixis's next earnings date.
Is Exelixis profitable or losing money?
As of the last Exelixis earnings report, Exelixis is currently profitable. Exelixis's net profit (also called net income) for the twelve months ending Mar 31, 2025 was $643.57 million, a 213.85% increase year over year.
What was EXEL's earnings growth in the past year?
As of Exelixis's earnings date in Invalid Date, Exelixis's earnings has grown 251.56% year over year. This is 240.03 percentage points higher than the US Biotechnology industry earnings growth rate of 11.53%. EXEL earnings in the past year totalled $643.57 million.
What are Exelixis's earnings expectations?
The current EPS estimate for Exelixis's earnings report in Invalid Date is $0.47.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.